

## **Attachment 1 Analysis of Atypical Antipsychotic Drugs**

### **GOALS:**

- To analyze the use of these agents as monotherapy at low doses
- To develop potential targets for a letter intervention

### **METHODS:**

All claims for the atypical antipsychotic drugs (aripiprazole, clozapine, olanzapine, quetiapine, risperidone, and ziprasidone) were extracted for Jan 2006 through March 2006. Data were aggregated to produce the daily dose by patient.

A query was run to select patients on only one atypical antipsychotic drug at doses below those normally used to treat schizophrenia, psychoses, or bipolar disease. The following doses were used:

- Abilify (aripiprazole)-less than 10 mg/day
- clozapine-less than 300 mg/day
- Geodon (ziprasidone)-less than 80 mg/day
- Risperdal (risperidone)-less than 2 mg/day
- Seroquel (quetiapine)-less than 300 mg/day
- Zyprexa (olanzapine)-5 mg or less per day

### **PRELIMINARY RESULTS:**

A table of the aggregated data is attached.

A summary of the findings includes:

- Almost seventy-five percent of patients on these drugs were on monotherapy
- Over 50 percent of patients on monotherapy are on low doses of atypical antipsychotics
- Over 75 percent of patients on Seroquel are on low doses, followed by Geodon, and Risperdal

The analysis suggests that there are a considerable number of prescriptions written for these drugs at doses below that recommended for the treatment of psychoses or bipolar disease. Possible reasons for this would include patients who are susceptible to these drugs and have adequate treatment at low doses, the use of these drugs for other non-approved indications, or inadequate treatment of the psychosis.

<b>DRUG</b>	<b>Count IDs in low dose</b>	<b>Count of unique patients on low dose monotherapy</b>	<b>Count of all patients on agent alone or in combo</b>	<b>Count of all patients on single agent</b>	<b>% of patients on monotherapy (E/D)</b>	<b>% of patients on monotherapy at low dose (C/E)</b>
Abilify	966	805	2697	1852	68.67%	43.5%
Clozapine	87	82	389	259	66.58%	31.7%
Geodon	577	457	1157	730	63.09%	62.6%
Seroquel	2438	2225	3938	2951	74.94%	75.4%
Risperdal	2122	1983	4393	3619	82.38%	54.8%
Zyprexa	513	479	1736	1308	75.35%	36.6%
<b>TOTAL</b>	<b>6703</b>	<b>6031</b>	<b>14310</b>	<b>10719</b>	<b>74.91%</b>	<b>56.3%</b>

**PROPOSAL:**

Develop an intervention modeled after the anti-epileptic drug intervention:

- Aggregate claims for patients meeting low dose criteria by prescriber
- Get aggregated costs by prescriber
- Rank order prescribers by dollars associated with claims meeting the low dose criteria
- Develop an intervention letter to prescribers about these agents

Include patient's recent claims and costs for patients associated with prescribers.